Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Table of Contents | Next Article »
Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:881-883

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tracy, R. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tracy, R. P.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Related Collections
Right arrow Obesity
Right arrow Pathophysiology
Right arrow Risk Factors
Right arrow Growth factors/cytokines
Right arrow Coagulation and fibronolysis
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:881.)
© 2001 American Heart Association, Inc.

Editorial

Is Visceral Adiposity the "Enemy Within"?

Russell P. Tracy

From the University of Vermont College of Medicine, Colchester.

Correspondence to Dr Russell P. Tracy, University of Vermont, Departments of Pathology and Biochemistry, 55A South Park Dr, Colchester, VT 05446.


Key Words: obesity • inflammation • cardiovascular disease

Recently, data from diverse areas of investigation have come together to implicate chronic low-level inflammation as an important pathogenetic factor in atherosclerotic cardiovascular disease (CVD). As recently summarized by Ross,1 studies in cell biology, animal models, clinical research, and epidemiology have been remarkably consistent in validating the early work of Virchow2 and others, suggesting that atherosclerotic lesions are essentially an inflammatory response. In clinical research and epidemiology, 2 inflammation blood markers in particular, fibrinogen and C-reactive protein (CRP), have been used. Many studies have confirmed that these markers predict future cardiovascular events independently of more traditional cardiovascular risk factors, such as plasma lipid levels.3 4 5 Because of this, several investigators have suggested that CRP might prove useful in clinical practice,6 7 whereas others have favored fibrinogen.8 9 Although there are important details to work out before either of these markers enters the clinical domain, this interest provides a clear and compelling imperative for understanding how inflammation integrates into both normal physiology and atherothrombotic pathophysiology.

Focusing on CRP, population-based research efforts have revealed that in general, women have slightly higher values than men, blacks have higher values than whites, and those with clinical CVD have higher values than those without10 11 12 13 (M. Cushman, et al, manuscript in preparation). In those without clinical CVD, metabolic variables consistently correlated with CRP include body mass index (BMI), glucose tolerance status/diabetes status, and level of coagulation activation. In addition, depending on the population being studied, other correlates of CRP may include smoking status, plasma lipids (especially HDL cholesterol), hypertension, evidence of chronic infection, and measures of subclinical atherosclerotic disease, such as ankle-brachial blood pressure index (ABI).

Whether or not some variables have been identified as significant correlates appears to depend, at least in part, on the presence and/or extent of other variables in the analysis. For example, in the nonsmokers of the Cardiovascular Health Study, diabetes status was a strong correlate of CRP but ABI was not; in the smokers, in whom pack-years of smoking was strongly correlated with CRP, diabetes status was no longer significant but ABI was.11 In another example, all measures related to carbohydrate metabolism were correlated with CRP in the Insulin Resistance and Atherosclerosis Study (IRAS), which had participants within a broad range of insulin sensitivity and diabetes status.12 Neither smoking nor measures of subclinical atherosclerosis such as carotid artery wall thickness, however, were correlated with CRP in this group. This variability in correlation suggests that unless significant acute inflammation is present, ambient levels of CRP and underlying regulators such as interleukin-6 are tightly regulated and rarely exceed upper limits. This is logical, because the underlying inflammation system appears to be pervasive and connected to a wide variety of homeostatic and defensive processes.14

Despite this variability in the association of some variables with CRP, a measure of obesity (usually BMI) has been relatively strongly correlated with CRP in virtually all analyses done to date. Two articles in the current issue of Arteriosclerosis, Thrombosis, and Vascular Biology address this now well-established association. Both articles extend our knowledge in this area and provide important new insights into the regulation of inflammation status. The report by Lemieux et al15 focuses on a detailed analysis of body composition in healthy middle-aged men with atherogenic dyslipidemia and a wide range of BMI (21 to 41 kg/m2). They used hydrostatic weighing and computed tomography to make state-of-the-art assessments of body fat, extending the work of Yudkin and others,10 11 13 finding strong positive correlations of CRP with body fat mass, waist girth, and visceral fat. Confirming the analysis done in IRAS,12 they also observed a strong relationship to insulin levels assessed over time during a 75-g oral glucose load. In this group of men, they failed to observe any significant association of CRP with plasma lipid levels, concluding that in men with atherogenic dyslipidemia associated with the metabolic syndrome, it is abdominal obesity that is the "critical correlate" of CRP.

These findings have several important implications. First, the data fit well with a growing body of evidence implicating adipose tissue in general, and visceral adiposity in particular, as key regulators of inflammation, coagulation, and fibrinolysis.16 Adipose tissue secretes proinflammatory cytokines13 17 and fibrinolytic regulators such as plasminogen activator inhibitor-1.18 Along with many possible roles in atherogenesis and atherosclerotic progression, inflammatory mediators can activate coagulation by stimulating monocytes to express tissue factor19 (as can CRP itself20 ) and by causing disregulation in natural anticoagulation.21 They can affect fibrinolytic balance22 and have been implicated as a possible pathogenetic agent in the development of insulin resistance,23 the latter being consistent with the ability of inflammation markers to predict the future occurrence of diabetes.24 As a major source of proinflammatory cytokines, adipose tissue becomes linked at the molecular level to the disregulation of a variety of underlying systems, all of which are causally implicated in the development of atherosclerotic, thrombotic, and metabolic outcomes.

Second, although subcutaneous fat clearly plays an important role,17 the identification of visceral adiposity as a key correlate of CRP in these men is consistent not only with the emerging role of abdominal fat in the metabolic syndrome25 but also with the concept of "nonoverweight obesity" as proffered by Dvorak and colleagues.26 They suggested that the role of visceral fat may be more complex than suspected, because even people who are not obviously overweight may still have disproportionately too much visceral fat, with the result of a predisposition toward insulin resistance and atherosclerotic disease, possibly through inappropriate cytokine secretion. If true, this concept begs the question of whether the key variable might not be disproportionate visceral adiposity rather than what has traditionally been considered obesity as characterized by weight, waist girth, or BMI.

Finally, adiposity may offer a target for modification of inflammation status. The evidence that inflammation is a pathogenetic factor in atherosclerosis is strong, and Lemieux et al conclude their article by suggesting that inflammation may be a modifiable risk factor, citing recent clinical trial data involving aspirin, statins, and fibrates.27 28 29 30 They also suggest that because of the powerful association with obesity, weight loss may be another method for downregulating an individual’s inflammatory status. This point is directly addressed by the second article, the report by Heilbronn et al.31 They studied a group of healthy obese women, characterized by an average BMI of 34 kg/m2, with a range of 28 to 44 kg/m2. These subjects were placed on a very-low-fat diet for 12 weeks and achieved an average weight loss of 8 kg. CRP decreased by 26%, and the authors observed a strong correlation between weight loss and change in CRP (r=0.3, P=0.005).

This observation has important health implications. Although there are no direct data involving CRP or the proinflammatory cytokines it reflects in human atherosclerotic disease, research using the murine model of atherosclerosis has shown such results,32 and the indirect data in humans are consistent and becoming compelling. From a mechanistic standpoint, several possible pathways for interleukin-6, tumor necrosis factor-{alpha}, and CRP have been identified, eg, the activation of monocytes and endothelial cells.20 33 Clinically, in the Physicians Health Study, the ability of aspirin to protect against a first CVD event was strongly linked to higher CRP levels,29 and statins appear to work most effectively in people with higher CRP values.27 28 Although the ability of aspirin to lower CRP is uncertain, statins clearly do so.34 35 Therefore, it is reasonable to hypothesize that other methods that have a CRP-lowering effect, such as weight loss, may prove more effective in those with higher CRP values (ie, higher ambient inflammatory status). Because CRP levels are also associated cross-sectionally with activity status,36 this finding suggests a similar hypothesis related to exercise.

We and others have recently observed that unlike statins, hormone replacement therapy in the form of estrogen, but not estrogen-like synthetic drugs, raises CRP levels dramatically.37 38 39 40 On the basis of observational studies, estrogen has traditionally been considered an influence for the better with regard to CVD risk. The recent results from the HERS trial, identifying a significant CVD risk for some women in the first year or so after the start of estrogen therapy,41 however, raise the question of whether drugs that raise CRP may carry an unwanted risk based on their effects on inflammation. In addition, one might ask whether those with greater visceral fat deposits might be at even greater risk because of a possibly increased potential for proinflammatory response. These hypotheses will be tested directly in several ongoing hormone replacement clinical trials.

In summary, an emerging body of evidence suggests that abdominal fat is a key regulatory site for the general processes of inflammation, coagulation, and fibrinolysis. These processes may be altered by behaviors, such as diet and exercise, that affect fat deposits, as well as by medications, in both positive and negative ways. These effects have long-term implications for chronic outcomes such as CVD and type 2 diabetes, which we are only beginning to understand.

References

  1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115–126.[Free Full Text]
  2. Virchow R. Die Cellularpathologie in ihrer Begründung auf physiologische und pathologische Gewebelehre. Berlin, Germany; 1858.
  3. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279:1477–1482.[Abstract/Free Full Text]
  4. Ridker PM. Novel risk factors and markers for coronary disease. Adv Intern Med. 2000;45:391–418.[Medline] [Order article via Infotrieve]
  5. Tracy RP. Inflammation markers and coronary heart disease. Curr Opin Lipidol. 1999;10:435–441.[Medline] [Order article via Infotrieve]
  6. Rifai N, Ridker PM. Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. Clin Chem. 2001;47:28–30.[Free Full Text]
  7. Tracy RP. Inflammation in cardiovascular disease: cart, horse, or both? Circulation. 1998;97:2000–2002.[Free Full Text]
  8. Ernst E, Koenig W. Fibrinogen and cardiovascular risk. Vasc Med. 1997;2:115–125.[Medline] [Order article via Infotrieve]
  9. Montalescot G, Collet JP, Choussat R, Thomas D. Fibrinogen as a risk factor for coronary heart disease. Eur Heart J. 1998;19(suppl H):H11–H17.
  10. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study [see comments]. BMJ. 1996;312:1061–1065.[Abstract/Free Full Text]
  11. Tracy R, Macy E, Bovill E, Cushman M, Psaty B, Cornell E, Kuller L. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol. 1997;17:2167–2176.[Abstract/Free Full Text]
  12. Festa A, D’Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42–47.[Abstract/Free Full Text]
  13. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999;19:972–978.[Abstract/Free Full Text]
  14. Aggawal B, Puri R, eds. Human Cytokines: Their Role in Disease and Therapy. Cambridge, Mass: Blackwell Science; 1995.
  15. Lemieux I, Pascot A, Prud’homme D, Alméras N, Bogaty P, Nadeau A, Bergeron J, Després J-P. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol. 2001;21:961–967.[Abstract/Free Full Text]
  16. Yudkin JS. Abnormalities of coagulation and fibrinolysis in insulin resistance: evidence for a common antecedent? Diabetes Care. 1999;22(suppl 3):C25–C30.
  17. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997;82:4196–4200.[Abstract/Free Full Text]
  18. Loskutoff DJ, Samad F. The adipocyte and hemostatic balance in obesity: studies of PAI-1. Arterioscler Thromb Vasc Biol. 1998;18:1–6.[Free Full Text]
  19. Gregory SA, Morrissey JH, Edgington TS. Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin. Mol Cell Biol. 1989;9:2752–2755.[Abstract/Free Full Text]
  20. Cermak J, Key N, Bach R, Balla J, Jacob H, Vercellotti G. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood. 1993;82:513–520.[Abstract/Free Full Text]
  21. Esmon C, Taylor F, Snow T. Inflammation and coagulation: linked processes potentially regulated through a common pathway mediated by protein C. Thromb Haemost. 1991;66:160–165.[Medline] [Order article via Infotrieve]
  22. Kluft C, Verheijen J, Jie A, Rijken D, Preston F, Sue-Ling H, Jespersen J, Aasen A. The post-operative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast acting inhibitor of tissue-type plasminogen activator after trauma. Scand J Clin Lab Invest. 1985;45:605–610.[Medline] [Order article via Infotrieve]
  23. Cheung AT, Ree D, Kolls JK, Fuselier J, Coy DH, Bryer-Ash M. An in vivo model for elucidation of the mechanism of tumor necrosis factor-alpha (TNF-alpha)-induced insulin resistance: evidence for differential regulation of insulin signaling by TNF-alpha. Endocrinology. 1998;139:4928–4935.[Abstract/Free Full Text]
  24. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, Azambuja MI, Tracy RP, Heiss G. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet. 1999;353:1649–1652.[Medline] [Order article via Infotrieve]
  25. Montague CT, O’Rahilly S. The perils of portliness: causes and consequences of visceral adiposity. Diabetes. 2000;49:883–888.[Abstract]
  26. Dvorak RV, DeNino WF, Ades PA, Poehlman ET. Phenotypic characteristics associated with insulin resistance in metabolically obese but normal-weight young women. Diabetes. 1999;48:2210–2214.[Abstract]
  27. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998;98:839–844.[Abstract/Free Full Text]
  28. Horne BD, Muhlestein JB, Carlquist JF, Bair TL, Madsen TE, Hart NI, Anderson JL. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. J Am Coll Cardiol. 2000;36:1774–1780.[Abstract/Free Full Text]
  29. Ridker P, Cushman M, Stampfer M, Tracy R, Hennekens C. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–979.[Abstract/Free Full Text]
  30. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature. 1998;393:790–793.[Medline] [Order article via Infotrieve]
  31. Heilbronn LK, Noakes M, Clifton MP. Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Atheroscler Thromb Vasc Biol. 2001;21:968–970.[Abstract/Free Full Text]
  32. Huber SA, Sakkinen P, Conze D, Hardin N, Tracy R. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 1999;19:2364–2367.[Abstract/Free Full Text]
  33. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102:2165–2168.[Abstract/Free Full Text]
  34. Strandberg TE, Vanhanen H, Tikkanen MJ. Effect of statins on C-reactive protein in patients with coronary artery disease [letter] [see comments]. Lancet. 1999;353:118–119.[Medline] [Order article via Infotrieve]
  35. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation. 2001;103:1191–1193.[Abstract/Free Full Text]
  36. Geffken DF, Cushman M, Burke GL, Polak JF, Sakkinen PA, Tracy RP. Association between physical activity and markers of inflammation in a healthy elderly population. Am J Epidemiol. 2001;153:242–250.[Abstract/Free Full Text]
  37. Cushman M, Meilahn EN, Psaty BM, Kuller LH, Dobs AS, Tracy RP. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol. 1999;19:893–899.[Abstract/Free Full Text]
  38. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, Sakkinen PA, Tracy RP. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation. 1999;100:717–722.[Abstract/Free Full Text]
  39. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation. 1999;100:713–716.[Abstract/Free Full Text]
  40. Walsh BW, Paul S, Wild RA, Dean RA, Tracy RP, Cox DA, Anderson PW. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab. 2000;85:214–218.[Abstract/Free Full Text]
  41. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group [see comments]. JAMA. 1998;280:605–613.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 CirculationHome page
L. J. Shaw, J. F. Lewis, M. A. Hlatky, W. A. Hsueh, S. F. Kelsey, R. Klein, T. A. Manolio, A. R. Sharrett, R. P. Tracy, and Endorsed by the American College of Cardiology Fou
Women's Ischemic Syndrome Evaluation: Current Status and Future Research Directions: Report of the National Heart, Lung and Blood Institute Workshop: October 2-4, 2002: Section 5: Gender-Related Risk Factors for Ischemic Heart Disease
Circulation, February 17, 2004; 109 (6): e56 - e58.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
R. Marfella, K. Esposito, M. Siniscalchi, F. Cacciapuoti, F. Giugliano, D. Labriola, M. Ciotola, C. Di Palo, L. Misso, and D. Giugliano
Effect of Weight Loss on Cardiac Synchronization and Proinflammatory Cytokines in Premenopausal Obese Women
Diabetes Care, January 1, 2004; 27(1): 47 - 52.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
R. P. Tracy
Thrombin, Inflammation, and Cardiovascular Disease: An Epidemiologic Perspective
Chest, September 1, 2003; 124(3_suppl): 49S - 57S.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. Esposito, A. Pontillo, F. Giugliano, G. Giugliano, R. Marfella, G. Nicoletti, and D. Giugliano
Association of Low Interleukin-10 Levels with the Metabolic Syndrome in Obese Women
J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1055 - 1058.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
C. R. Isasi, R. J. Deckelbaum, R. P. Tracy, T. J. Starc, L. Berglund, and S. Shea
Physical Fitness and C-Reactive Protein Level in Children and Young Adults: The Columbia University BioMarkers Study
Pediatrics, February 1, 2003; 111(2): 332 - 338.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
H. M. Colhoun, C. Schalkwijk, M. B. Rubens, and C. D.A. Stehouwer
C-Reactive Protein in Type 1 Diabetes and Its Relationship to Coronary Artery Calcification
Diabetes Care, October 1, 2002; 25(10): 1813 - 1817.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. Esposito, A. Pontillo, M. Ciotola, C. Di Palo, E. Grella, G. Nicoletti, and D. Giugliano
Weight Loss Reduces Interleukin-18 Levels in Obese Women
J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3864 - 3866.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
T. B. Harris
Invited Commentary: Body Composition in Studies of Aging: New Opportunities to Better Understand Health Risks Associated with Weight
Am. J. Epidemiol., July 15, 2002; 156(2): 122 - 124.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
P. Ziccardi, F. Nappo, G. Giugliano, K. Esposito, R. Marfella, M. Cioffi, F. D'Andrea, A. M. Molinari, and D. Giugliano
Reduction of Inflammatory Cytokine Concentrations and Improvement of Endothelial Functions in Obese Women After Weight Loss Over One Year
Circulation, February 19, 2002; 105(7): 804 - 809.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tracy, R. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tracy, R. P.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Related Collections
Right arrow Obesity
Right arrow Pathophysiology
Right arrow Risk Factors
Right arrow Growth factors/cytokines
Right arrow Coagulation and fibronolysis

ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.